Expression and characterization of recombinant canine IL-13 receptor α2 protein and its biological activity in vitro

Molecular Immunology

Volumn 39, Issue 12, 2003, Pages 719-727

  Tang, Liang ^a,b   Morales, Tony ^a,c   Boroughs, Karen L ^a   Lo Keiser, Kathy Cailles ^a,d   Sellins, Karen ^a   Stedman, Kim ^a   McCall, Catherine ^a,e   McDermott, Martin J ^a,f  

^a HESKA CORPORATION   (United States)

^b BAYER CORPORATION   (United States)

^c ARRAY BIOPHARMA INC   (United States)

^d Pharmaceutical Product Development   (United States)

^e BioStar Inc   (United States)

^f GILEAD SCIENCES   (United States)

Author keywords

Canine cytokine; IgE; IL 13; IL 13 receptor

Indexed keywords

IMMUNOGLOBULIN E; INTERLEUKIN 13 RECEPTOR;

ALLERGIC ASTHMA; ANIMAL CELL; ARTICLE; CELL INCLUSION; CELL PROLIFERATION; CONTROLLED STUDY; DOG; DRUG ACTIVITY; ESCHERICHIA COLI; IMMUNOGLOBULIN PRODUCTION; IN VITRO STUDY; ION EXCHANGE CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ALLERGENS; ANIMALS; ASTHMA; BASE SEQUENCE; CELL LINE; DNA, COMPLEMENTARY; DOGS; ESCHERICHIA COLI; GENE EXPRESSION; HUMANS; IMMUNOGLOBULIN E; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA1 SUBUNIT; LEUKOCYTES, MONONUCLEAR; PROTEIN FOLDING; RECEPTORS, INTERLEUKIN; RECEPTORS, INTERLEUKIN-13; RECOMBINANT PROTEINS; RNA, MESSENGER;

CANIS FAMILIARIS; SIPHONAPTERA (FLEAS);

EID: 0037229531     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(02)00258-4     Document Type: Article

References (32)

1. Borish L.C., Nelson H.S., Lanz M.J., Claussen L., Whitmore J.B., Agosti J.M., Garrison L. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160:1999;1816-1823.
2. Borish L.C., Nelson H.S., Corren J., Bensch G., Busse W.W., Whitmore J.B., Agosti J.M. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107:2001;963-970.
3. Brinkmann, V., Kinzel, B., 1997. IL-4 and IL-13 in atopy: regulation of production and effects. In: Vercelli, D. (Ed.), IgE Regulation: Molecular Mechanisms. Wiley, New York.
4. Burd P.R., Thompson W.C., Max E.E., Mills F.C. Activated mast cells produce interleukin 13. J. Exp. Med. 181:1995;1373-1380.
5. Caput D., Laurent P., Kaghad M., Lelias J.M., Lefort S., Vita N., Ferrara P. Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain. J. Biol. Chem. 27:1996;16921-16926.
6. Casale T.B., Bernstein I.L., Busse W.W., LaForce C.F., Tinkelman D.G., Stoltz R.R., Dockhorn R.J., Reimann J., Su J.Q., Fick R.B., Adelman D.C. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 100:1997;110-121.
7. Chiaramonte M.G., Schopf L.R., Neben T.Y., Cheever A.W., Donaldson D.D., Wynn T.A. L-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J. Immunol. 162:1999;920-930.
8. Chomarat P., Banchereau J. Interleukin-4 and interleukin-13: their similarities and discrepancies. Int. Rev. Immunol. 17:1998;1-52.
9. Corry D.B. IL-13 in allergy: home at last. Curr. Opin. Immunol. 11:1999;610-614.
10. Debinski W., Obiri N.I., Powers S.K., Pastan I., Puri R.K. Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and pseudomonas exotoxin. Clin. Cancer Res. 1:1995;1253-1258.
11. Debinski W., Gibo D.M., Hulet S.W., Connor J.R., Gillespie G.Y. Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin. Cancer Res. 5:1999;985-990.
12. de Waal Malefyt R., Abrams J.S., Zurawski S.M., Lecron J.C., Mohan-Peterson S., Sanjanwala B., Bennett B., Silver J., de Vries J.E., Yssel H. Differential regulation of IL-13 and IL-4 production by human CD8+ and CD4+ Th0, Th1 and Th2 T cell clones and EBV-transformed B cells. Int. Immunol. 7:1995;1405-1416.
13. Donaldson D.D., Whitters M.J., Fitz L.J., Neben T.Y., Finnerty H., Henderson S.L., O'Hara R.M. Jr., Beier D.R., Turner K.J., Wood C.R., Collins M. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J. Immunol. 161:1998;2317-2324.
14. Fahy, J.V., 2000. Reducing IgE levels as a strategy for the treatment of asthma. Clin. Exp. Allergy (Suppl. 1), 16-21.
15. Fahy J.V., Fleming H.E., Wong H.H., Liu J.T., Su J.Q., Reimann J., Fick R.B., Boushey H.A. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med. 155:1997;1828-1834.
16. Fick R.B. Anti-IgE as novel therapy for the treatment of asthma. Curr. Opin. Pulm. Med. 5:1999;76-80.
17. Grünig G., Warnock M., Wakil A.E., Venkayya R., Brombacher F., Rennick D.M., Sheppard D., Mohrs M., Donaldson D.D., Locksley R.M., Corry D.B. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 282:1998;2261-2263.
18. Huang S.K., Xiao H.Q., Kleine-Tebbe J., Paciotti G., Marsh D.G., Lichtenstein L.M., Liu M.C. IL-13 expression at the sites of allergen challenge in patients with asthma. J. Immunol. 155:1995;2688-2694.
19. Jardieu P.M., Fick R.B. IgE inhibition as a therapy for allergic disease. Int. Arch. Allergy Immunol. 118:1999;2-4.
20. Li L., Xia Y., Nguyen A., Lai Y.H., Feng L., Mosmann T.R., Lo D. Effects of Th2 in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol. 162:1999;2477-2487.
21. MacGlashan D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., Sterbinsky S.A., Hamilton R.G., Lichtenstein L.M. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J. Immunol. 158:1997;1438-1445.
22. Maini A., Hillman G., Haas G.P., Wang C.Y., Montecillo E., Hamzavi F., Pontes J.E., Leland P., Pastan I., Debinski W., Puri R.K. Interleukin-13 receptors on human prostate carcinoma cell lines represent a novel target for a chimeric protein composed of IL-13 and a mutated form of Pseudomonas exotoxin. J. Urol. 158:1997;948-953.
23. Milgrom H., Fick R.B., Su J.Q., Reimann J.D., Bush R.K., Watrous M.L., Metzger W.J. Treatment of allergic asthma with monoclonal anti-IgE antibody. rhuMAb-E25 Study Group. N. Engl. J. Med. 341:1999;1966-1973.
24. Minty A., Asselin S., Bensussan A., Shire D., Vita N., Vyakarnam A., Wijdenes J., Ferrara P., Caput D. The related cytokines interleukin-13 and interleukin-4 are distinguished by differential production and differential effects on T lymphocytes. Eur. Cytokine Netw. 8:1997;203-213.
25. Redman T.K., Rudolph K., Barr E.B., Bowen L.E., Muggenburg B.A., Bice D.E. Pulmonary immunity to ragweed in a beagle dog model of allergic asthma. Exp. Lung Res. 27:2001;433-451.
26. Shields R.L., Whether W.R., Zioncheck K., O'Connell L., Fendly B., Presta L.G., Thomas D., Saban R., Jardieu P. Inhibition of allergic reactions with antibodies to IgE. Int. Arch. Allergy Immunol. 107:1995;308-312.
27. Tang L. Molecular cloning of canine IL-13 receptor α chain (α1 and α2) cDNAs and detection of corresponding mRNAs in canine tissues. Vet. Immunol. Immunopath. 79:2001;181-195.
28. Tang L., Boroughs K.L., Morales T., Stedman K., Sellins K., Clarke K., McDermott M., Yang S., McCall C. Recombinant canine IL-13 receptor (2-Fc fusion protein inhibits canine allergen-specific-IgE production in vitro by peripheral blood mononuclear cells from allergic dogs. Vet. Immunol. Immunopathol. 83:2001;115-122.
29. Tripp, C.A., Selkirk, M.E., Grieve, R.B., 1996. Dirofilaria immitis Gp29 proteins, nucleic acid molecules and uses thereof. US Patent No. 5.569.603, issued 29 October 1996.
30. Wills-Karp M., Luyimbazi J., Xu X., Schofield B., Neben T.Y., Karp C.L., Donaldson D.D. Interleukin-13: central mediator of allergic asthma. Science. 282:1998;2258-2261.
31. Yang S., Boroughs K., McDermott M.J. Canine Interleukin-13: molecular cloning of full-length cDNA and expression of biologically active recombinant protein. J. Interf. Cytokine Res. 20:2000;779-785.
32. Zhang J.G., Hilton D.J., Willson T.A., McFarlane C., Roberts B.A., Moritz R.L., Simpson R.J., Alexander W.S., Metcalf D., Nicola N.A. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein. Evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J. Biol. Chem. 272:1997;9474-9480.